Drug/Small Molecule:

famotidine

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. PubChem (source: Drug Bank)

For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). (source: Drug Bank)

Famotidine binds competitively to H₂-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. (source: Drug Bank)

Famotidine, a competitive histamine H₂-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. (source: Drug Bank)

Avoid alcohol.
Limit caffeine intake.
Take without regard to meals, food may slightly increase the product's bioavailability. (source: Drug Bank)

Hepatic. (source: Drug Bank)

15-20% (source: Drug Bank)

The bioavailability of oral doses is 40-45%. (source: Drug Bank)

Intravenous, mouse: LD₅₀ = 244.4mg/kg; Oral, mouse: LD₅₀ = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse. (source: Drug Bank)

c1c(nc(s1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N (source: Drug Bank)